Blood And Marrow Transplantation
Blood stem cells derived from donor bone marrow resulted in better self-reported psychological well-being and fewer GVHD symptoms.
Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant PatientsJuly 01, 2016
Researchers recently identified CXCL10, a protein that could act as a biomarker for chronic graft-versus-host disease (cGVHD), a long-term adverse effect that develops in some patients after undergoing blood and bone marrow transplant.
Sources of stem cells used to treat bone marrow failure vary around the world, with bone marrow harvest more commonly used in areas with more resources. PBSCs are more commonly used in regions with limited resources.
Nursing staff satisfaction improved in transition of care for patients from the inpatient to the outpatient blood and marrow transplant (BMT) units.
This review discusses common risk factors, treatment, and preventive measures for aspergillosis in hematopoietic stem transplantation recipients.
A subset of antiviral immune cells could prevent CMV infections in bone marrow transplant recipientsFebruary 24, 2015
A small subset of antiviral immune cells may be enough to fight and even prevent the disease caused by cytomegalovirus (CMV) in patients that receive bone marrow transplants.
A new test can assist in the treatment of patients with graft-versus-host disease (GVHD), an often life-threatening complication of bone marrow and stem cell transplants.
Patients with Hodgkin lymphoma who received brentuximab vedotin after transplantation lived longer without disease progression than patients who received only supportive care, per clinical trial data.
A simple questionnaire that rates breathing difficulties on a scale of 0 to 3 predicts survival in chronic graft-vs-host disease, according to a new study.
Preparative procedures and complications associated with blood or bone marrow transplantation have been tied to diminished sexual health in both men and women, according to new research.
A certification program in blood and marrow transplantation nursing is being offered by the Oncology Nursing Certification Corporation, with the first BMTCN examination scheduled for February 2014.
Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).
A novel method has been developed to determine how ready acute myeloid leukemia (AML) cells are to die. This discovery may help to more effectively choose treatment options for patient with AML.
The immune systems of transplant recipients and lymphoma patients tend to be significantly depressed, making these patients more susceptible to melanoma, according to a review on the role of immunosuppression in melanoma.
Greater difficulty exists in finding matched, unrelated donors for nonwhite patients who are candidates for hematopoietic cell transplantation (HCT), according to a study by researchers at the Moffitt Cancer Center.
Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient's unexplained neurologic symptoms.
The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.
Drug Safety Communication on lenalidomide (Revlimid); FDA approval for pazopanib (Votrient)
Three patients with glioblastoma lived longer than predicted after receiving transplants of their own blood stem cells that had been gene-modified.
This review describes the four major groups of leukemia, plus diagnostic tests and treatment regimens for each group.
Challenges to the future growth of allogeneic blood and marrow transplants (BMT)—currently, more than 20,000 are performed annually in the United States alone—include workforce shortages and lack of adequate infrastructure, according to a presentation during the Oncology Nursing Society 36th Annual Congress.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|